To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • Publication number: 20140288093
    Abstract: The present disclosure provides technologies relating to lysosomal activation. The disclosure provides several strategies for increasing level and/or activity of lysosomal enzyme, and furthermore demonstrates the surprising applicability of such strategies in the treatment and/or prophylaxis of certain proteinopathies. Among other things, the present invention provides methods and compositions for the treatment and/or prophylaxis of proteinopathies other than lysosomal storage diseases through lysosomal activation. In particular, the present disclosure provides methods and compositions for the treatment and/or prophylaxis of neurodegenerative proteinopathies, and in particular those associated with accumulation of ?-synuclein. The present disclosure specifically provides methods and compositions for the treatment and/or prophylaxis of Parkinson's disease.
    Type: Application
    Filed: June 22, 2012
    Publication date: September 25, 2014
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Dmitri Krainc, Joseph R. Mazzulli
  • Publication number: 20140287943
    Abstract: The present disclosure is directed to detecting colon disorders by measuring the expression of SHIP1 in a sample of PBMCs. One method includes the following steps, obtaining a sample including peripheral blood mononuclear cells (PBMCs) from a subject and determining whether SHIP1 is underexpressed in the PBMCs or lacks normal enzymatic activity. The present disclosure is also directed to a method of determining the expression of SHIP1 protein expression and SHIP1 enzyme activity in PBMCs. This method includes the following steps, obtaining a sample comprising PBMCs from a subject and determining the amount of SHIP1 in the PBMCs.
    Type: Application
    Filed: April 27, 2012
    Publication date: September 25, 2014
    Applicants: ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM, THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
    Inventors: William G. Kerr, Gwenny M. Fuhler, Sandra Fernandes
  • Publication number: 20140287432
    Abstract: The present invention relates to methods for the diagnosis, prevention and treatment of heart disease or heart failure in a subject. The present invention also relates to methods for the diagnosis, prevention and treatment of atherosclerosis with vulnerable plaque in a subject. Furthermore, the present invention relates to methods for the diagnosis, prevention and treatment of cardiomyopathies resulting from Chagas disease.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 25, 2014
    Inventor: Maria de Lourdes Higuchi
  • Publication number: 20140287434
    Abstract: The present invention relates to drug screening assays, therapeutic protocols and pharmaceutical compositions designed to target non-receptor tyrosine family kinases and components of the tyrosine kinase family signal transduction pathways. This includes primarily diseases or conditions associated with immune responses and can include treatment for cancers as well as various immune disorders. The invention reports a novel substrate SH2 domain docking mechanism apart from the kinase active site that is required for appropriate tyrosine phosphorylation by these tyrosine kinases.
    Type: Application
    Filed: May 8, 2014
    Publication date: September 25, 2014
    Inventors: Amy H. Andreotti, Raji E. Joseph, Lie Min
  • Publication number: 20140286932
    Abstract: Provided herein are methods and kits for evaluating potential for invasiveness, metastasis, or recurrence of an epithelial cell cancer. In the methods the expression profile of giant obscurins is detected in a tissue sample of tumor cells or suspected tumor cells and assessed for giant obscuring expression level and distribution therein. Decreased levels or altered distribution of giant obscurins in the cells compared to a control non-invasive standard or to a sample taken at a different point in time is indicative of increased potential of at least one of the invasiveness, metastasis, or recurrence of the epithelial cell cancer. The kit comprises a detection reagent suitable for detecting the presence and distribution of giant obscurins or an amount of the gene product(s) encoding giant obscurins in cells of a tissue sample and instructions for using the detection reagent.
    Type: Application
    Filed: March 21, 2014
    Publication date: September 25, 2014
    Applicants: JOHNS HOPKINS UNIVERSITY, UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Aikaterini Kontrogianni-Konstantopoulos, Konstantinos Konstantopoulos, Marey Shriver, Nicole Perry
  • Publication number: 20140287955
    Abstract: The present invention pertains inter alia to a method for analysing a sample comprising biomolecules, which comprises the following steps: A a) lysing the sample to provide a lysed sample and optionally clearing the lysed sample; b) contacting at least a portion of the lysed sample with a dry composition comprising reagents for performing the analytical method, thereby providing a reconstituted composition; c) performing an analytical method using the reconstituted composition; or B a) contacting the sample with a lysis solution thereby providing a lysis mixture; b) using the lysis mixture to reconstitute a dry composition comprising reagents for performing the analytical method, thereby providing a reconstituted composition; c) performing an analytical method using the reconstituted composition, wherein the reconstituted composition is optionally cleared and wherein subsequent to step b) at least one step is performed which supports the lysis of the sample.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 25, 2014
    Inventors: Andy Wende, Rainer Dahlke, Ralf Himmelreich, Thomas Rothmann, Michael Eberhard, Gerd Grosshauser, Markus Jeziorski, Hans Attig, Josef Drexler, Eva Holzer
  • Patent number: 8841083
    Abstract: Disclosed herein are novel synthetic prostate specific antigen (PSA)-targeted capture agents that specifically bind PSA. In certain embodiments, these PSA capture agents are biligand or triligand capture agents containing two or three target-binding moieties, respectively.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: September 23, 2014
    Assignees: California Institute of Technology, Indi Molecular, Inc.
    Inventors: James R. Heath, Heather Dawn Agnew, Suresh Mark Pitram
  • Patent number: 8841084
    Abstract: Disclosed herein are methods of detecting and/or prognosing myocardial infarction by detecting a proteolytic fragment of caspase-3 such as the p17 fragment or the p12 fragment. The myocardial infarction can be STEMI or NSTEMI.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: September 23, 2014
    Assignees: The University of Connecticut, Mayo Foundation for Medical Education and Research
    Inventors: Bruce T. Liang, Heiko Schmitt, Michael Azrin, Christopher C. Pickett, Allan S. Jaffe
  • Publication number: 20140271926
    Abstract: A method of treating neoplastic growth in a subject includes administering a glutamine synthetase (GS) inhibitor to the subject having neoplastic growth. A glutamine synthetase inhibitor may be administered in combination with thalidomide, lenalidomide and/or pomalidomide. Responsiveness to thalidomide, lenalidomide or pomalidomide therapy is determined by the expression levels of glutamine synthetase in neoplastic cells.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Thang V. Nguyen, Raymond J. Deshaies
  • Publication number: 20140273008
    Abstract: Methods to assess biological enzyme activity directly in a complex clinical sample. To such a sample, e.g., plasma, an exogenous synthetic peptide substrate for an enzyme present in the sample and to be assessed is added. The sample then undergoes mass spectrometric immunoassay (MSIA) to monitor the mass spectral profile of the immuno-purified exogenous synthetic peptide substrate directly from the sample. Using the resulting profile, parameters such as enzyme activity and effect of enzyme modulators, including therapeutics administered to an individual for a condition involving the enzyme, may be determined.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Molecular BioProducts, Inc.
    Inventors: Urban A. Kiernan, Eric E. Niederkofler
  • Publication number: 20140274891
    Abstract: This application relates to methods of predicting susceptibility or likelihood of a clinically-relevant mannose-binding lectin (MBL)-deficient subject to develop a cardiovascular disease and/or cardiodiabetes. The methods include measuring MBL mass or concentration and, optionally, measuring MBL activity, at least one other biomarker and/or genotyping of MBL gene and its promoters; combining the information obtained into a calculated MBL-inclusive index score that involves mathematical transformation; and assigning a risk of cardiadiabetic status and clinical endpoints based on the determination and comparison of the MBL inclusive index to reference values from a population.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicant: Health Diagnostic Laboratory, Inc.
    Inventors: Rebecca E. Caffrey, James Pottala, Stephen Varvel
  • Publication number: 20140272964
    Abstract: This invention provides methods of making and using a fluorescent probe from the Sandercyanin protein as set forth in SEQ ID NO: 1 or SEQ ID NO: 2. In one embodiment, the invention provides a method of creating a fluorescent probe, comprising the steps of attaching a Sandercyanin moiety to a probe, wherein the probe is specific to a desired target.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: WiSys Technology Foundation, Inc.
    Inventors: Wayne Schaefer, Ramaswamy Subramanian, Daniel Ferraro, Chi Li Yu, David Gibson, Swagatha Ghosh, P. Sai Sudha
  • Publication number: 20140274798
    Abstract: Substrates are provided that include compounds suitable for detecting the activity of an enzyme such as a lysosomal storage enzyme where the substrates include: a sugar moiety; a linker moiety allowing the conjugation of sugar moiety with the remaining structure of the substrate; and two or more fatty acid chains or derivatives thereof at least one of which is sufficiently structured to provide improved solubility in aqueous or organic solvent systems. Also provided are methods for using substrates for detecting enzymatic activity using the inventive substrates.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Applicants: University of Washington Through its Center for Commercialization, PerkinElmer Health Sciences, Inc.
    Inventors: Alexander Cherkassky, Jason Cournoyer, Michael Gelb
  • Publication number: 20140275073
    Abstract: The present disclosure provides methods of treating cancer and modifying a cancer treatment for a cancer with an anti-EGFR drug by creating PRDX6 expression profiles and using the profiles to evaluate and optionally modify treatment. The present disclosure also provides assays and systems for assessing sensitivity of a cancer to an anti-EGFR therapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Inventors: Edwin Chang, Lingyun Xu, Nick Hughes, Carsten H. Nielsen, Sanjiv S. Gambhir, Parag Mallick, Arutselvan Natarajan
  • Publication number: 20140273007
    Abstract: A diagnostic test system, apparatus and method for identifying individuals at risk for developing or having breast cancer by detection of at least one marker associated with increased breast cancer risk in nipple aspirate fluid is provided. A testing device for screening nipple aspirate fluid for the presence of biomarkers associated with breast cancer and methods of identifying individual biomarkers and biomarker panels for evaluating the risk that an individual has developed or will develop breast cancer by assaying nipple aspirate fluid is described.
    Type: Application
    Filed: March 11, 2014
    Publication date: September 18, 2014
    Applicant: DR. SUSAN LOVE RESEARCH FOUNDATION
    Inventor: Susan Love
  • Publication number: 20140274766
    Abstract: Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and/or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and/or growth and mediating the alleviation of bone disease, disorders or conditions.
    Type: Application
    Filed: January 15, 2014
    Publication date: September 18, 2014
    Inventors: Steven B. Abramson, Mukundan Attur, Glyn Palmer, Ashok Amin
  • Publication number: 20140274739
    Abstract: Flow chambers are provided. In some embodiments, the flow chambers include an inner panel having at least one flow channel having an inlet/outlet opening on each end thereof formed therein, wherein the inlet/outlet openings are adapted to releasably receive a septum; one or more ports adapted to releasably receive a plug and for at least liquid communication with the at least one flow channel, and an outer frame that defines an outer portion of the at least one flow channel and that defines a perimeter of the flow chamber. In some embodiments, the flow chamber has overall dimensions of a standard multiwell plate and the at least one flow channel is located in a position that corresponds to a column location of the standard multiwell plate. Also provided are methods for producing the presently disclosed flow chambers and employing the same to assay biological features of cultured cells and/or tissues.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: UNIVERSITY OF CALGARY
    Inventors: Kristina D. Rinker, Robert D. Shepherd
  • Publication number: 20140274882
    Abstract: Provided herein are methods for detecting an Aspergillus protease in a sample, diagnosing a subject with aspergillosis caused by an Aspergillus infection based on the presence of an Aspergillus protease in a sample, and methods of aspergillosis treatment that incorporate these diagnostic methods. In certain embodiments, the Aspergillus protease is Asp f2, and the Aspergillus infection is caused A. fumigatus, A. flavus, A. versicolor, A. niger, or A. terreus. Also provided herein are antibodies and kits for use in these methods, including novel antibodies specific for Asp f2.
    Type: Application
    Filed: March 17, 2014
    Publication date: September 18, 2014
    Inventors: Markus KALKUM, Karine BAGRAMYAN, Diana DIAZ-AREVALO, James I. ITO, Sanjeet DADWAL
  • Publication number: 20140274782
    Abstract: Methyl-lysine affinity reagents created by engineering the 3×MBT methyl-lysine binding domain repeat of lethal (3) malignant brain tumor-like protein 1 (L3MBTL1) are disclosed. In particular, the invention relates to affinity reagents and affinity chromatography media comprising the 3×MBT domain repeat and methods of using such affinity reagents in detection, purification, and proteomic profiling of methylated proteins and peptides.
    Type: Application
    Filed: March 15, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Scott M. Carlson, Or Gozani, Kaitlyn E. Moore
  • Patent number: 8835144
    Abstract: Dual-functional nonfouling surfaces and materials, methods for making dual-functional nonfouling surfaces and materials, and devices that include dual-functional nonfouling surfaces and materials. The dual-functional surfaces are nonfouling surfaces that resist non-specific protein adsorption and cell adhesion. The dual-functional surfaces and materials include covalently coupled biomolecules (e.g., target binding partners) that impart specific biological activity thereto. The surfaces and materials are useful in medical diagnostics, biomaterials and bioprocessing, tissue engineering, and drug delivery.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: September 16, 2014
    Assignee: University of Washington
    Inventors: Shaoyi Jiang, Zheng Zhang, Shengfu Chen, Hana Vaisocherova
  • Patent number: 8835171
    Abstract: This invention is based in part on the elucidation of new structural conformations and functions of the sodium/potassium adenosine triphosphate synthase (Na/K ATPase), and especially elucidation of new binding sites and interactions. The present invention provides practical applications of several surprising structural and functional relationships between Na/K ATPase and compounds which interact with Na/K ATPase. Disclosure of these structures and relationships provides insight and practical solutions to chemically affecting not only the Na/K ATPase interactions, but also regulators known to be upstream and downstream.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: September 16, 2014
    Assignee: The University of Toledo
    Inventors: Zi-Jian Xie, Yiliang Chen, Haojie Wang
  • Publication number: 20140256564
    Abstract: The present invention relates to methods of identifying gene targets, including methods of using ribonucleoprotein (RNP) immunoprecipitation-microarrays to identify cancer gene targets, such as subsets of RNP-associated mRNAs in breast cancer cell lines. Also presented, are ribonucleotide binding protein-associated biomarkers, panels or sets of ribonucleotide binding protein-associated biomarkers, methods and compositions comprising ribonucleotide-binding protein, associated nucleotides, nucleotide arrays, and kits, plus methods of using HuR-associated biomarkers to facilitate the diagnosis of, monitoring the disease status of, and the progression of treatment of breast cancers to facilitate the diagnosis of and monitoring the disease status or progression of treatment of breast cancers, including drug-resistant breast cancers.
    Type: Application
    Filed: February 5, 2014
    Publication date: September 11, 2014
    Applicant: The Curators of the University of Missouri
    Inventors: Ulus ATASOY, Robert CALALUCE, Justin Wade DAVIS
  • Publication number: 20140255953
    Abstract: A method for identifying a subject being at risk for or having a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease is provided. The method may include determining the concentration of GrA and/or GrB in a blood or serum sample from said subject; and comparing the concentrations to the corresponding concentration in a control sample, wherein an elevated concentration of GrA and/or GrB may be indicative of a chronic inflammatory disease, fibrillinopathy, atherosclerosis, or coronary artery disease. The method may further include identifying concentrations of fibrinogen, elastin and/or fibrillin.
    Type: Application
    Filed: April 25, 2014
    Publication date: September 11, 2014
    Applicant: THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: David Granville, Rani Cruz, Ciara Chamberlain, Wendy Boivin, Bruce McManus
  • Publication number: 20140255312
    Abstract: Compounds used as labels with properties comparable to known fluorescent compounds. The compounds can be conjugated to proteins and nucleic acids for biological imaging and analysis. Synthesis of the compounds, formation and use of the conjugated compounds, and specific non-limiting examples of each are provided.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 11, 2014
    Inventors: Greg Hermanson, Peter T. Czerney, Surbhi Desai, Matthias S. Wenzel, Boguslawa R. Dworecki, Frank G. Lehmann
  • Publication number: 20140255952
    Abstract: The invention relates to carbon nanotube-containing composites as biosensors to detect the presence of target clinical markers, methods of their preparation and uses in the medical field. The invention is particularly suitable for the detection in patient biological specimens of bone markers and tissue markers. The biosensors of the invention include carbon nanotubes deposited on a substrate, gold nanoparticles deposited on the carbon nanotubes and, binder material and biomolecule deposited on the gold-coated carbon nanotubes. The biomolecule is selected to interact with the target clinical markers. The biosensor can be used as an in-situ or an ex-situ device to detect and measure the presence of the target clinical markers.
    Type: Application
    Filed: March 5, 2014
    Publication date: September 11, 2014
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: PRASHANT NAGESH KUMTA, MADHUMATI RAMANATHAN, MITALI SHIRISH PATIL
  • Publication number: 20140255313
    Abstract: The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications.
    Type: Application
    Filed: January 3, 2014
    Publication date: September 11, 2014
    Inventors: Olga Vasiljeva, Elizabeth-Edna Mary Menendez
  • Publication number: 20140255393
    Abstract: Methods and compositions are described for categorizing and treating autoimmune disease, using single cell network profiling (SCNP), where activation levels of one or more activatable elements are determined in single cells, with or without modulation, to categorize or determine treatment for the autoimmune disease.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 11, 2014
    Applicant: Nodality, Inc.
    Inventors: Jason Ptacek, Rachael Hawtin, Erik Evensen, James Cordeiro, Alessandra Cesano
  • Publication number: 20140255951
    Abstract: The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.
    Type: Application
    Filed: February 4, 2014
    Publication date: September 11, 2014
    Applicant: Gilead Biologics, Inc.
    Inventors: Scott Alan MCCAULEY, Hector RODRIGUEZ, Carlos Aurelio GARCIA, Victoria SMITH
  • Patent number: 8828685
    Abstract: Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: September 9, 2014
    Assignee: The Scripps Research Institute
    Inventors: Paul Schimmel, Xiang-Lei Yang, Bonnie Slike
  • Publication number: 20140249121
    Abstract: The present relates to a method for detecting cardiac remodeling in a subject without clinical signs of heart failure comprising determining the level of the NGAL-MMP9 complex in a blood sample obtained from the patient.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 4, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Frederic Jaisser, Patrick Rossignol, Faiez Zannad
  • Publication number: 20140248635
    Abstract: Polypeptides with tubulin acetyltransferase activity are described, as are nucleic acids encoding said polypeptides, and methods of use. The invention further provides enhancers and inhibitors of tubulin acetyltransferase activity, as well as cells having altered tubulin transferase activity.
    Type: Application
    Filed: February 4, 2014
    Publication date: September 4, 2014
    Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Jacek Gaertig, Dorota Wloga, Shilpa Akella
  • Publication number: 20140249152
    Abstract: The present invention discloses that diabetic rats showed a reduction in nitrergic relaxation of the gastric, impaired nNOS dimerization, decreased BH4 and GTPCH1 levels and thus, are more susceptible to develop diabetic gastroparesis. The use of tetrahydrobiopterin and its derivatives and sex steroid hormones as disclosed herein provides a novel strategy for therapeutic intervention of diabetic gastroparesis and any other gut-related diseases. Additionally, the present invention also discloses methods to determine risk of developing gastroparesis in an individual that are drawn to detecting variations in the activity and levels of GCH gene and in gene encoding sex steroid hormone receptor.
    Type: Application
    Filed: March 6, 2014
    Publication date: September 4, 2014
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Pankaj J. Pasricha, Pandu R.R. Gangula
  • Publication number: 20140248636
    Abstract: The present invention relates to assays for monitoring activity of Mina53 and NO66 activities, in particular, to assays for identifying modulators of Mina53 and NO66 activities. The invention also relates to assays to monitor the histidinyl hydroxylase activity of Mina53 and NO66 on their substrates, the human ribosomal protein Rpl27a and Rpl8 respectively. The invention also enables the introduction of S-3-hydroxyhistidinyl residues into peptides and proteins.
    Type: Application
    Filed: July 25, 2012
    Publication date: September 4, 2014
    Applicant: Isis Innovation Limited
    Inventors: Christopher Joseph Schofield, Wei Ge, Matthew Edward Cockman, Peter John Ratcliffe, Mathew Louis Coleman
  • Publication number: 20140248637
    Abstract: Disclosed is as a biomarker useful in early diagnosis of lung cancer, at least one protein selected from the group including Quescin-sulfhydryl oxidase 1, Fibrillin-1, Isoform A of Lamin-A/C, Latent-transforming growth factor beta-binding protein 2, Galectin-1, highly similar to Dickkopf-related protein 3, Isoform A1-B of Heterogeneous nuclear ribonucleoprotein A1, 14-3-3 protein epsilon, Stanniocalcin-2, Cystatin-C, Isoform 1 of Connective tissue growth factor, Profilin-1, Isoform 1 of Extracellular matrix protein 1, Histone H2B type 2-E, Kinesin-like protein KIF26A, Zinc finger protein 516, and Isoform 1 of A-kinase anchor protein 9.
    Type: Application
    Filed: May 14, 2014
    Publication date: September 4, 2014
    Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
    Inventors: Je Yoel CHO, Hye Jin SUNG
  • Publication number: 20140249045
    Abstract: Provided is a method of screening for agents for preventing or treating mTORC1 mediated diseases by screening test agents to determine test agents that inhibit the binding ability of LRS to RagD, or RagD GTPases, and a method of reducing cell size as compared to the control group, including inhibiting the expression of intracellular LRS in the cells.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 4, 2014
    Applicant: Medicinal Bioconvergence Research Center
    Inventors: Sunghoon KIM, Jung Min Han
  • Publication number: 20140248284
    Abstract: The present invention relates to methods and kits for detecting cardiac remodeling in subjects without clinical signs of heart failure. The present invention also relates to methods and pharmaceutical compositions for the prevention and the treatment of cardiac remodeling.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 4, 2014
    Inventors: Faiez Zannad, Patrick Rossignol
  • Publication number: 20140249048
    Abstract: Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.
    Type: Application
    Filed: May 13, 2014
    Publication date: September 4, 2014
    Applicant: Phadia AB
    Inventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
  • Publication number: 20140242607
    Abstract: It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-?1,6-N-acetylglucosaminyltransferase 5B antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase ?1,6-N-acetylglucosaminyltransferase 5B as an epithelial ovarian cancer marker. The antibody recognizes, as an epitope, a part of a polypeptide of the enzyme consisting of the amino acid sequence represented by SEQ ID NO: 1.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 28, 2014
    Applicant: National Institute of Advanced Industrial Science and Technology
    Inventors: Maki Sogabe, Tomomi Kubota, Akira Togayachi, Yuzuru Ikehara, Hisashi Narimatsu, Hiromichi Sawaki, Hayao Nakanishi, Toru Nakanishi
  • Publication number: 20140242092
    Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.
    Type: Application
    Filed: May 13, 2014
    Publication date: August 28, 2014
    Applicant: Agency For Science, Technology And Research (A*STAR)
    Inventor: Qi Zeng
  • Publication number: 20140242606
    Abstract: The present invention relates to a probe for iFRET and use thereof. Specifically, the present invention relates to a novel probe for iFRET, a method for preparing the probe for iFRET, a method for searching a target protein-specific binding site or a molecule having the binding site using the probe for iFRET, and a method for imaging the target protein using the probe for iFRET. The probe for iFRET according to the present invention utilizes an amino acid in a protein as a fluorescent donor, unlike the conventional FRET method. Therefore, only one fluorescent material is used, and its emission wavelength is distinct from the intrinsic fluorescence of the protein. Thus, high specificity and sensitivity are ensured, and the quantity, activity and mechanism of various proteins can be analyzed in an easy and accurate manner.
    Type: Application
    Filed: June 25, 2012
    Publication date: August 28, 2014
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Sang Jeon Chung, Ju Hwan Kim, Elena Ruchkina, Hyo Jin Kang
  • Publication number: 20140242591
    Abstract: A method of providing protection against pneumococcal infection in a subject is disclosed. The method includes steps of administering to the subject a composition that includes combination of three recombinant pneumococcal neuraminidases: NanA, NanB, and NanC of S. pneumoniae strains CGSP14, wherein administration of the recombinant pneumococcal neuraminidases elicits an immune response to S. pneumoniae, and treats the subject. In one embodiment, the method further includes a step of adding adjuvants to enhance the immune response. The method also includes a step of using passive antibodies, wherein said passive antibodies are anti-neuraminidase antibodies generated from neuraminidases-immunized humanized animals: NanA, NanB, and NanC. Meanwhile, this invention also provides a method for the molecular diagnosis of pneumococcal infection.
    Type: Application
    Filed: February 25, 2013
    Publication date: August 28, 2014
    Applicant: CHANG GUNG MEDICAL FOUNDATION, LINKOU BRANCH
    Inventors: Cheng-Hsun Chiu, Rajendra Prasad Janapatla, Chyi-Liang Chen, Mei-Hua Hsu, Hsiu-Ling Chen, Chung-Tsui Huang, Hsin-Ju Chang, Wan-Ting Liao
  • Publication number: 20140243211
    Abstract: Biomarkers and methods for screening expression levels of the biomarkers for predicting and tracking suicidality, as well as for monitoring response to a treatment for suicidal risk and for determining suicidal risk as a side-effect of an antidepressant are disclosed.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 28, 2014
    Inventor: Alexander B. Niculescu
  • Patent number: 8815233
    Abstract: A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: August 26, 2014
    Assignee: Curemark LLC
    Inventor: Joan M. Fallon
  • Patent number: 8815527
    Abstract: The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: August 26, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Omar D. Perez, Garry P. Nolan
  • Publication number: 20140234861
    Abstract: A method for diagnosing acute coronary syndrome (ACS) in a subject, the method comprising measuring plasma macrophage migration inhibitory factor (MIF) concentration in a sample from the subject, and diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, wherein the sample is taken less than 4 hours after symptom onset. The invention also relates to a method for prognosing ACS in a subject, the method comprising measuring plasma MIF concentration in a sample from the subject, diagnosing ACS when the subject plasma MIF concentration is greater than a reference plasma MIF concentration, and prognosing the magnitude of ACS from the subject plasma MIF concentration. Also provided is a method of treating ACS in a subject, a device, a kit, and a cardiac biomarker related to the methods of diagnosing and prognosing ACS.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 21, 2014
    Inventor: Anthony Dart
  • Publication number: 20140234321
    Abstract: This invention relates generally to a novel serine/threonine protein kinase, specifically to hormonally up-regulated, neu-tumor-associated kinase (HUNK); and to the role of HUNK in tumor metastasis, primary tumor development, and the prediction of tumor behavior.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 21, 2014
    Applicant: The Trustees of The University of Pennsylvania
    Inventors: Lewis A. CHODOSH, Gerald Wertheim, Thomas W. Yang
  • Publication number: 20140235490
    Abstract: Provided herein is a large immuno-sorbent surface area assay (ALISSA) for the rapid and sensitive detection of botulinum neurotoxins (BoNTs) and anthrax toxin. This assay is designed to capture a low number of toxin molecules and to measure their intrinsic protease activity via conversion of a fluorogenic or luminescent substrate. Also provided herein are novel peptides that can be specifically cleaved by BoNT and novel peptides that are resistant to cleavage by BoNT. The combination of these cleavable and control peptides can be used for implementation of an exemplary ALISSA used to specifically detect BoNT enzymatic activity. Furthermore, the ALISSA as described herein may also be used in a column based format for use in a high-throughput system for testing large quantities of samples.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 21, 2014
    Applicant: CITY OF HOPE
    Inventors: Markus KALKUM, Karine BAGRAMYAN
  • Publication number: 20140235479
    Abstract: The present invention provides methods of detecting cancer using biomarkers.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 21, 2014
    Inventors: Ronald A. Depinho, Zhihu Ding, Lynda Chin
  • Publication number: 20140234347
    Abstract: The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods.
    Type: Application
    Filed: January 17, 2014
    Publication date: August 21, 2014
    Applicant: Immatics Biotechnologies GmbH
    Inventors: Toni WEINSCHENK, Harpreet Singh, Andrea Mahr, Jens Fritsche
  • Publication number: 20140235707
    Abstract: The invention provides methods for predicting the efficacy of eribulin, an analog thereof, or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate), in the treatment of a subject suffering from breast cancer by determining the level of particular biomarkers in a sample derived from the subject.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 21, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Sergei I. Agoulnik, Michael Chapman Byrne, Bruce A. Littefield